For more information1.800.263.0016

Products

TD Cannabase

Introduction

Cannabase™ is a lipid based transdermal delivery system which is developed for the transdermal delivery of lipophilic Phytoceuticals such as Phytocannabinoids 1. This base can be used as a Transdermal delivery system for Cannabinoid molecules and other lipophilic phytoceuticals with synergistic anti-inflammatory and analgesic effect in the management of difficult to treat pain 2-5. 

Cannabase transdermal cream offers cosmetically appealing texture while enabling deep penetration of lipophilic actives.

 

 

Available Sizes:

100G, 500G, 18KG

Where to buy

Cannabase™ is a lipid based transdermal delivery system which is developed for the transdermal delivery of lipophilic Phytoceuticals such as Phytocannabinoids 1. This base can be used as a Transdermal delivery system for Cannabinoid molecules and other lipophilic phytoceuticals with synergistic anti-inflammatory and analgesic effect in the management of difficult to treat pain 2-5.

Cannabase Cream Highlighted Benefits

  • Cosmetically appealing
  • Non-greasy cream base
  • Enhanced dermal penetration of lipophilic phytoceuticals such as Cannabinoids
  • Easy to incorporate Cannabinoids
  • Can incorporate essential oils, extracts and active phytoceuticals. 
  • The non-tacky feature differentiates the cream from other products available in the market
  • Heat is not required to dissolve the active ingredient

 Application

  • Transdermal delivery of lipophilic Phytoceuticals 

 

Essential Oil Compatibility Chart

Essential Oil

Common Concentration (s)

Essential Oil

Common Concentration (s)

Argan Oil

1 to 8%

Myrrh Essential Oil

1 to 3%

Eucalyptus Essential Oil

1 to 3%

Peppermint  Essential Oil

1 to 3%

Grapefruit Essential Oil

1 to 3%

Rose Hip  Essential Oil

0.5 to 3%

Hemp Oil

1 to 3%

Tea Tree  Essential Oil

1 to 5%

Jojoba Oil

1 to 3%

 

 

Thyme Essential Oil

0.5 to 2%

Lavender  Essential  Oil

1- 2.5%

 

 

Spearmint  Essential Oil

1 to 3%

Moringa Oil

1 to 2%

Winter Green Essential Oil

1 to 3%

 

Compounding Tips:

It is suggested to levigate the active ingredient in powder or resin form using a wetting agent such Ethoxy Diglycol prior to mixing with the cream base. Essential oils or the terpene of choice can be used as levigating agent as well. 

 

References

1. Bruni N1, Della Pepa C2, Oliaro-Bosso S3, Pessione E4, Gastaldi D5, Dosio F6., Cannabinoid Delivery Systems for Pain and Inflammation Treatment,  Molecules. 2018 Sep 27;23(10).

2. Manzanares J, Julian M, Carrascosa A., Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol. 2006 Jul;4(3):239-57.

3. Russo E, Cannabinoids in the management of difficult to treat pain, Ther Clin Risk Manag. 2008 Feb; 4(1): 245–259.

4. Guindon J, De Léan A, Beaulieu P. Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain. 2006 Mar;121(1-2):85-93. Epub 2006 Feb 9.

5. https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids.html#a2.2.1.6

 

 

 

 

 

Disclaimer: Transderma Pharmaceuticals Inc. has provided the formula and instructions above as a model for educational purposes only on the basis of recognized compendia and texts or references. Transderma Pharmaceuticals Inc. takes no responsibility for the validity or accuracy of this information or for its safety or effectiveness, nor for any use thereof, which is at the sole risk of the licensed pharmacist. Adjustments may be needed to meet specific patient needs and in accordance with a licensed prescriber’s prescription. The pharmacist must employ appropriate tests to determine the stability of this suggested formula. Transderma Pharmaceuticals Inc., its owners, officers, agents, contractors, affiliates and employees cannot be held liable to any person or entity concerning claims, loss or damage caused by, or alleged to be caused by, directly or indirectly, the use or misuse of the information contained in this suggested formula. In all cases, it is the responsibility of the licensed pharmacist to know the law, to compound any finished product and to dispense these products in accordance with Health Canada and FDA guidelines and appropriate Provincial Drug Schedules and Provincial or Territorial Pharmacy Practice Standards.

Toll Free: 1.800.663.1002
Website: www.xenexlabs.com

Xenex has been supplying the highest quality products, delivered by qualified professionals to the Canadian compounding profession for over 30 years. Xenex focuses on the compounding pharmacist and has built a valuable set of support services to provide the pharmacist with education, formulation support and competitively priced product, delivered by a knowledgeable sales and customer services team.